Please login to the form below

Not currently logged in
Email:
Password:

Tagrisso

This page shows the latest Tagrisso news and features for those working in and with pharma, biotech and healthcare.

AZ forecasts growth in 2021 after revenues surge in Q4

AZ forecasts growth in 2021 after revenues surge in Q4

In 2020, oncology growth was up by 23% to $11.45bn, with the top-selling product being AZ’s EGFR-tyrosine kinase inhibitor Tagrisso (osimertinib).

Latest news

More from news
Approximately 29 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    Cancer therapies Tagrisso (osimertinib) – now AZ’s top-selling drug – Lynparza (olaparib) and Imfinzi (durvalumab) are already gathering momentum, as they rack up additional indications that extend their use and there ... Tagrisso’s growth as it

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    Now the business has two particularly strong growth drivers: emerging markets, most especially China, and oncology, where a triumvirate of drugs – Tagrisso, Imfinzi and Lynparza – have hit a major growth phase. ... Two leading examples of this are

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... EvaluatePharma forecasts that Lynparza (now co

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA)’s Priority Review pathway, ... Liang had been instrumental in building up the company’s

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics